What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained

The short version

What is tirzepatide? It is a weekly injection approved by the FDA to treat type 2 diabetes, obesity, and obstructive sleep apnea — and it works differently from earlier drugs in this class.

Most drugs in this category activate one gut hormone signal (GLP-1). Tirzepatide activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both hormones are released from the gut after eating and help the pancreas release insulin only when blood sugar is actually high — which is why this class of drug has a low risk of causing dangerously low blood sugar on its own.

Because tirzepatide hits both receptors, its effects in clinical trials were larger than those seen with single-receptor drugs. In the biggest obesity trial (SURMOUNT-1), people on the top dose lost about 21% of their body weight over 72 weeks — one of the largest effects ever recorded in a drug trial for obesity ^[4].

It is given as a subcutaneous (under the skin) injection once a week. The dose starts low and steps up over several months to help manage side effects, mainly nausea and digestive discomfort.

What is tirzepatide: the compound and its approvals

Tirzepatide is a synthetic 39-amino-acid peptide whose backbone is based on the native GIP hormone sequence. It was developed by Eli Lilly and Company under the research designation LY3298176 and received FDA approval for type 2 diabetes in May 2022 and for chronic weight management in adults with obesity or overweight with a weight-related condition in November 2023 ^[12][15]. A further approval for moderate-to-severe obstructive sleep apnea in adults with obesity followed ^[16].

It is classified as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual receptor agonist — sometimes called a "twincretin" or "dual incretin mimetic" to distinguish it from earlier GLP-1 receptor agonists. The molecule's structure includes a C20 fatty-diacid modification that allows it to bind reversibly to albumin in plasma, extending the half-life to approximately five days and enabling once-weekly dosing ^[1].

Tirzepatide is approved only for use in adults. The prescribing information notes it is not approved for type 1 diabetes ^[7]. Its approved indications do not include off-label uses, and it carries a boxed warning regarding the risk of thyroid C-cell tumours based on rodent data, with a contraindication in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[12].

The incretin effect: why activating two receptors matters

Incretins are gut-derived peptide hormones that amplify meal-stimulated insulin secretion. The key property is that the amplification is glucose-dependent: the incretin effect is active only when blood glucose is elevated. That mechanism is what makes incretin-based drugs different from older insulin secretagogues, which can lower blood sugar even when levels are already normal.

GIP and GLP-1 are the two principal incretins. Both are secreted from enteroendocrine cells in the small intestine after eating. Together they are responsible for roughly 50–70% of the insulin response to a mixed meal — a phenomenon called the incretin effect.

In people with type 2 diabetes, the GLP-1 response to meals is blunted. GIP secretion is relatively preserved but the GIP receptor response may be impaired. By activating both receptors with a single molecule, tirzepatide is designed to engage the full incretin axis simultaneously. In vitro assays and the clinical disposition-index data confirm that the dual engagement produces larger improvements in both insulin secretion rate and insulin sensitivity than selective GLP-1 agonism ^[2][8].

For the full mechanistic walkthrough, see tirzepatide mechanism of action.

What the approvals mean: indications and the off-label boundary

The FDA approval for type 2 diabetes covers adjunct use in adults with inadequate glycaemic control on diet and exercise. The obesity approval covers chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition. The sleep apnea approval covers moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity ^[16].

In the SURMOUNT-OSA trial (n=469), tirzepatide reduced the apnea-hypopnea index (the number of breathing interruptions per hour of sleep, used to grade OSA severity) by 25 events per hour in participants not using CPAP therapy, with 42% of those participants achieving OSA resolution ^[16].

In the SUMMIT trial, tirzepatide improved a primary composite of heart failure events or cardiovascular death in adults with heart failure with preserved ejection fraction (HFpEF — a form of heart failure in which the heart's pumping fraction remains normal) and obesity ^[17].

For the MASH (metabolic dysfunction-associated steatohepatitis — a progressive fatty liver disease characterised by liver inflammation and fibrosis, formerly called NASH) indication, the SYNERGY-NASH trial produced positive results and regulatory review is active ^[18].

None of these approvals extends to non-approved populations, use as a performance-enhancing agent, or type 1 diabetes. This site documents what the trials measured. For the full Tirzepatide research record, see the research page.